VRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Verona Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $224.99 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Verona Pharma's Book Value per Share for the quarter that ended in Mar. 2024 was $2.78. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Verona Pharma's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.23.
The historical data trend for Verona Pharma's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verona Pharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 42.74 | 184.85 | 148.01 | 230.47 | 249.28 |
Verona Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 276.75 | 273.09 | 263.53 | 249.28 | 224.99 |
Verona Pharma (NAS:VRNA) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Verona Pharma's Book Value per Share for the quarter that ended in Mar. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (224.988 | - | 0) | / | 80.9215 | |
= | 2.78 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Verona Pharma's Debt-to-Equity for the quarter that ended in Mar. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (1.118 | + | 50.15) | / | 224.988 | |
= | 0.23 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Verona Pharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Martin Edwards | director | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
David R Ebsworth | director | C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Kathleen A. Rickard | officer: Chief Medical Officer | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Christina Ackermann | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Claire Poll | officer: General Counsel | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Mark W Hahn | officer: Chief Financial Officer | 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517 |
David Zaccardelli | director, officer: President and CEO | 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Rishi Gupta | director, 10 percent owner | C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Access Industries Holdings Llc | 10 percent owner | C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019 |
Ai Biotechnology Llc | 10 percent owner | C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Access Industries Management, Llc | 10 percent owner | 730 FIFTH AVENUE, NEW YORK NY 10019 |
Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
James Aloysius Brady | director | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Lisa Deschamps | director | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
From GuruFocus
By Marketwired • 08-31-2023
By GuruFocus Research • 11-02-2023
By Marketwired • 10-06-2023
By Marketwired • 11-02-2023
By PurpleRose PurpleRose • 08-24-2022
By Value_Insider Value_Insider • 10-17-2022
By sperokesalga sperokesalga • 05-09-2023
By Value_Insider Value_Insider • 12-19-2022
By Marketwired • 06-28-2023
By Marketwired • 10-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.